Rochester,NY 7/7/2009 4:02:57 AM
After Market - ILMN -Biotech firm Illumina will sequence your entire genetic code -- and throw in a Mac -- for $48,000.- Sourced WhisperFromWallStreet.com
Illumina Inc
After Market - ILMN -Biotech firm Illumina will sequence your entire genetic code -- and throw in a Mac -- for $48,000.- Sourced WhisperFromWallStreet.com
http://whisperfromwallstreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks a day to find those that meet our criteria and when we find one, we send you an alert. We have sent out 40 alerts so far in 2009 with an average price gain of over 80%. Please join risk free and see for yourself.
Sign up for our FREE alerts at WhisperfromWallStreet.com
---
Illumina Inc.ILMN
After Hours: 32.94 0.00 (0.00%) 4:40PM ET
Price competition is coming to the rarified world of genome sequencing.
For $48,000, San Diego-based Illumina (ILMN) will sequence your genome -- in other words, your entire genetic code.
Until now, the only other company offering personal genome sequencing services is biotech startup Knome. It charges $99,500.
Genome sequencing can alert individuals if they have inherited genes that cause illnesses like diabetes, Alzheimer's or cancer. Using the information as a guide, people could alter their lifestyles in an attempt to dodge potentially latent diseases. They also could find out the probability of passing along a genetic disease like cystic fibrosis to their children, or uncover interesting details about their ancestry.
Illumina is tossing in an iMac computer loaded with a customer's genetic data to round out the deal. But spending nearly $50K on a genetic code will not fit most people's budgets, even though that pricetag is hundreds of millions of dollars cheaper than sequencing the first human genome in 2003. Illumina says it expects just tens, perhaps hundreds, of people to sign up for the service within the next year.
About
Illumina, Inc. engages in the development, manufacture, and marketing of integrated systems for the analysis of genetic variation and biological function. Its instrumentation products include Genome Analyzer II, an instrument for high-throughput sequencing using Illumina sequencing by synthesis technology; iScan System, a high-resolution imaging instrument to scan BeadArray based assays; and BeadXpress Reader, a low- to mid-multiplex, high-throughput instrument for readout of assays. The company?s consumables comprise Standard Sequencing Kit, a reagent used for sequencing by synthesis chemistry on the Genome Analyzer; Paired-End Genomic DNA Sample Prep Kit, a streamlined library preparation kit to generate 200?500 kb insert paired-end reads; InfiniumHD Whole-Genome BeadChips comprising Human1M-Duo, Human610-Quad, Human660W-Quad, and HumanCytoSNP-12, which are multi-sample DNA analysis microarrays that interrogate up to 1.2 million markers per sample; iSelect Custom Genotyping BeadChips that are customer designable SNP genotyping arrays for 6,000 to 200,000 markers; and Whole-Genome Gene Expression BeadChips, which are multi-sample expression profiling arrays with up-to-date content for human, mouse, and rat. Illumina was founded in 1998 and is headquartered in San Diego, California.
Last Trade: 32.94
Day's Range: 32.33 - 33.30
52wk Range: 18.82 - 47.88
Volume: 3,807,267
---
Here are a few alerts our WhisperfromWallStreet.com subscribers enjoyed.
SPNG 1000%
AMNG 241%
RKBD 300%
UTRM 169%
TLLE 266%
Sign up to receive free stock alerts
---
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
